Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
Form 4 filing overview: On 06/27/2025 ATAI Life Sciences N.V. (symbol: ATAI) reported a change in beneficial ownership by Christian Angermayer, who is both a Director and 10% owner.
Key transaction: On 06/26/2025 the insider received a stock option covering 103,000 common shares at an exercise price of $2.25 per share. The award was coded "A" (grant or award) and is held directly by the reporting person.
Vesting & expiration: The option vests on the earlier of (i) the day before ATAIs next annual shareholder meeting or (ii) 06/26/2026, and it expires on 06/26/2035. No deemed execution date or other conditions were noted.
Post-transaction holdings: Following the grant, Mr. Angermayer beneficially owns 103,000 derivative securities (stock options). Table I shows no non-derivative share acquisitions or dispositions.
Investor take-away: The filing reflects a routine equity incentive grant rather than an open-market purchase or sale, so it carries limited immediate signalling value. The award incrementally increases potential dilution but has no direct impact on ATAIs cash position or current share count.